© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer | Clinical
Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors
November 17, 2020
In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.
Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer
November 15, 2020
Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial.
FDA Approves Pembrolizumab Plus Chemotherapy for PD-L1+ Locally Recurrent Unresectable or Metastatic TNBC
November 13, 2020
The FDA granted approval to pembrolizumab in combination with chemotherapy as treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1.
Hormone Receptor, pCR May Point to Survival on Dual HER2 Blockade
November 11, 2020
Updated data reported from a phase 3 trial show that patients with HER2- positive early breast cancer had better rates of overall survival after experiencing a pathologic complete response on HER2-targeted therapy, and these responses were observed most often in those with hormone receptor–negative status.
TNBC Heterogeneity Opens Door for Emerging Targeted Therapies
October 26, 2020
As a greater understanding of triple-negative breast cancer heterogeneity develops over time, combinations of PD-1/PD-L1 plus PARP inhibitors, androgen receptor targeted agents, and PI3K/AKT/mTOR pathway inhibitors are undergoing evaluation by investigators in the field.
Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer
October 22, 2020
Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.
Investigators Tailor TNBC Therapy Using Genomic Alterations
October 21, 2020
In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia G. Kaklamani, MD, DSc, reviewed the current genomic tools in the triple negative breast cancer landscape that predict response to targeted treatments.
Expert Insights on Metastatic Breast Cancer Awareness Day: Treating Patients by Subtype
October 13, 2020
A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.
Leading Research From ESMO 2020 Further the Potential of Targeted Agents in Breast Cancer
October 09, 2020
Breast cancer data reported during the 2020 European Society Medical Oncology Virtual Congress revealed major advances in the treatment paradigm. The agents included in these trials challenged that standard-of-care.
Palbociclib Combination Misses Primary End Point of PENELOPE-B in HR+, HER2- Early Breast Cancer
October 09, 2020
Palbociclib in combination with standard endocrine therapy did not improve invasive disease-free survival in patients with hormone receptor-positive, HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy, missing the primary end point of the phase 3 PENELOPE-B trial.